Breast Care· 2016Q2· Review
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- 30,918citations
- Q2SCImago
- 2016year
Short summary
Immune checkpoint inhibition, specifically blocking PD-1 and PD-L1, shows significant promise for treating breast cancer, particularly triple-negative subtypes, potentially leading to long-term disease control.
AI-generated from the title and abstract; the full text is not read.
Key points
- PD-1/PD-L1 blockade is a significant advance in treating breast cancer.
- This therapy shows impressive antitumor activity.
- It may lead to durable long-term disease control, particularly in TNBC.
- Immune-related adverse events (irAEs) are a potential side effect.
AI-generated from the title and abstract; the full text is not read.
Abstract
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
The authors' abstract, as published at the source. Breast Care, 2016 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Oncology
OncologyMedicine